Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery (LI-CTD)
Primary Purpose
Breast Cancer
Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Lidocaine mucilage-ICG
Sponsored by

About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring Breast conserving surgery; fluorescence-guided surgery
Eligibility Criteria
Inclusion Criteria:
- Female at least 18 years old
- Histologically or cytologically confirmed breast carcinoma
- Patients planned to receive a breast-conserving surgery
- Patients received a preoperative breast magnetic resonance imaging
- Informed consent form understood and signed
- Patient agrees to all follow-up visits
- Eastern Cooperative Oncology Group(ECOG) performance status 0 to 1 within 14 days of study entry
- Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the surgery
Exclusion Criteria:
- Psychiatric or other condition that may interfere with the study
- Known allergy or contraindication to any study drug
- Patients received neoadjuvant therapies
- Patients received an excision biopsy of the tumor
- Breast feeding period
- Pregnant (female of childbearing potential only)
Sites / Locations
- Shantou Central HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Efficacy of Lidocaine mucilage-ICG
Arm Description
Efficacy of Lidocaine mucilage-ICG for intraoperative tumor delineation
Outcomes
Primary Outcome Measures
Margin width
The distance between tumor and margin on the gross specimen
Positive margin rate
The percentage of patients with a positive margin out of the participants
Secondary Outcome Measures
Full Information
NCT ID
NCT04438577
First Posted
June 17, 2020
Last Updated
October 20, 2020
Sponsor
Shantou Central Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04438577
Brief Title
Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery
Acronym
LI-CTD
Official Title
Evaluation of the Feasibility and Efficacy of Lidocaine Mucilage-ICG as an Optical Agent to Detect Cancer Tissue Delineation During Breast-conserving Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Recruiting
Study Start Date
August 20, 2020 (Actual)
Primary Completion Date
July 2021 (Anticipated)
Study Completion Date
January 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shantou Central Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Around 15%-30% of patients receiving breast-conserving surgery (BCS) for invasive breast carcinoma or ductal carcinoma in situ (DCIS) need a reoperation due to tumor-positive margins at final histopathology. Currently available modalities used for intraoperative surgical margin assessment all have specific limitations. In order to improve intraoperative tumor localization and surgical margin assessment in BCS, we developed a fluorescent tracer, the Lidocaine mucilage-ICG tracer, which could be locally injected and detected by fluorescent camera systems during operation. In this study, we aim to evaluate the efficacy of Lidocaine mucilage-ICG as an agent for intraoperative tumor delineation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
Breast conserving surgery; fluorescence-guided surgery
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Efficacy of Lidocaine mucilage-ICG
Arm Type
Experimental
Arm Description
Efficacy of Lidocaine mucilage-ICG for intraoperative tumor delineation
Intervention Type
Drug
Intervention Name(s)
Lidocaine mucilage-ICG
Intervention Description
Lidocaine mucilage-ICG as an agent for intraoperative tumor delineation
Primary Outcome Measure Information:
Title
Margin width
Description
The distance between tumor and margin on the gross specimen
Time Frame
7 days
Title
Positive margin rate
Description
The percentage of patients with a positive margin out of the participants
Time Frame
7 days
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female at least 18 years old
Histologically or cytologically confirmed breast carcinoma
Patients planned to receive a breast-conserving surgery
Patients received a preoperative breast magnetic resonance imaging
Informed consent form understood and signed
Patient agrees to all follow-up visits
Eastern Cooperative Oncology Group(ECOG) performance status 0 to 1 within 14 days of study entry
Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the surgery
Exclusion Criteria:
Psychiatric or other condition that may interfere with the study
Known allergy or contraindication to any study drug
Patients received neoadjuvant therapies
Patients received an excision biopsy of the tumor
Breast feeding period
Pregnant (female of childbearing potential only)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mian-Han Zhuang
Phone
008613750445342
Email
jgbst@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Si-Qi Qiu, Dr.
Organizational Affiliation
Shantou Central Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shantou Central Hospital
City
Shantou
State/Province
Guangdong
ZIP/Postal Code
515300
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Si-Qi Qiu, Dr.
Phone
008613790868950
Email
s_patrick@163.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery
We'll reach out to this number within 24 hrs